Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14832425 | 0.81 | KMT2A (0.35) | MEN1KMT2APLGLMNACYP3A4 | |
| SCHEMBL12161361 | 0.81 | KMT2A (0.35) | MEN1KMT2APLGLMNACYP3A4 | |
| SCHEMBL14553365 | 0.81 | KMT2A (0.35) | MEN1KMT2APLGLMNACYP3A4 | |
| SCHEMBL19442208 | 0.70 | PLG (0.35) | MEN1KMT2APLGLMNACYP3A4 | |
| SCHEMBL1004978 | 0.70 | MEN1 (0.36) | MEN1KMT2APLGLMNACYP3A4 | |
| SCHEMBL12148580 | 0.67 | — | — | |
| SCHEMBL13626225 | 0.67 | MIF (0.30) | — | |
| SCHEMBL25253638 | 0.63 | IRAK4 (0.35) | KMT2A | |
| SCHEMBL27367158 | 0.63 | IRAK4 (0.32) | KMT2A | |
| SCHEMBL6961435 | 0.63 | PLG (0.35) | PLGCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | PFAS, GFPT1, PFKFB4 | MEN1 2965/4885KMT2A 1393/4885PLG 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.